ORIGINAL ARTICLE

Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro

N Haruki, K S Kawaguchi, S Eichenberger, P P Massion, A Gonzalez, A F Gazdar, J D Minna, D P Carbone, T P Dang

....

See end of article for authors' affiliations
....

Correspondence to:
T P Dang, Vanderbilt-Ingram Cancer Center, 642 PRB, Nashville, TN 37232, USA; thao.p.dang@vanderbilt.edu

Background: Somatically acquired chromosomal translocation is a common mechanism of oncogene activation in many haematopoietic tumours and sarcomas. However, very few recurrent chromosomal translocations have been reported in more common epithelial tumours such as lung carcinomas.
Methods: We established a cell line HCC2429 from an aggressive, metastatic lung cancer arising in a young, non-smoking woman, demonstrating a t(15;19)(q13.2;p13.1). The breakpoints on chromosomes 15 and 19 were cloned using long distance inverse PCR and we determined by RT-PCR that the translocation results in a novel fusion transcript in which the 3′ end *Brd4* on chromosome 19p is fused to the 5′ end of *NUT* on chromosome 15q.
Results: In total, 128 lung cancer tissues were screened using fluorescent in situ hybridisation, but none of the tumours screened demonstrated t(15;19), suggesting that this translocation is not commonly found in lung cancer. Consistent with previous literature, ectopic expression of wild type Brd4 was shown to inhibit G_1 to S progression. However, we also found that the Brd4-NUT fusion augments the inhibition of progression to S phase compared with wild type Brd4.
Conclusion: Alteration in cell cycle kinetics is important in tumorigenesis, although the exact role of Brd4-NUT fusion protein in the pathogenesis of lung cancers remains unclear and need to be further elucidated.

Cancer arises from the accumulation of genetic abnormalities associated with loss of expression, inappropriate gain of expression, or functional mutations. Chromosomal aberrations are hallmarks of virtually all types of cancer, and the study of these genetic abnormalities has given great insight into the genetic basis of cancer and into important growth regulatory pathways in normal cells. A well established mechanism for genetic alterations in haematopoietic malignancies involves the translocation of genetic material from one chromosome to another, resulting in the dysregulation of cellular proto-oncogenes or the generation of a novel chimeric protein with growth promoting activities. However, in lung carcinomas, the majority of the genetic abnormalities have been activating point mutations of dominant oncogenes, or deletion and/or inactivating mutations in tumour suppressor genes. Balanced translocations such as those observed in haematopoietic tumours have not been frequently documented in lung cancers. The study of translocations in epithelial tumours may thus reveal novel mechanisms important in lung cancer oncogenesis.

We previously described a t(15;19)(q13.2;p13.1) in a lung tumour from a 34 year old non-smoking woman who presented at the Vanderbilt Cancer Center with metastatic lung cancer. In the previous study, using fluorescence in situ hybridisation (FISH) on metaphase arrested cells, with Southern blot analysis, we mapped the translocation to approximately 50 kb upstream of the *Notch3* gene and showed that translocations involving chromosome 19 were associated with overexpression of this gene.[1] In the current study, we cloned the breakpoint and further localised it to a region on chromosome 19 between exon 11 and 12 of a recently described gene, *Brd4,* from a bromodomain family. Bromodomain is a conserved 110 amino acid motif found in several eukaryotic transcription factors, such as histone acetyltransferases, which specifically interacts with acetyl lysines in the context of histones H3 and H4.[2] The interruption in *Brd4* by the translocation suggests that the

translocation may alter the activity of Brd4, and the importance of bromodomain in transcription factors and cell cycle suggests that Brd4 may play a significant role in oncogenesis when dysregulated. Using long distance inverse PCR (LDI-PCR), we determined that the translocation results in a novel product fusing the 3′ end of *Brd4* to the intact transcript of a gene called *NUT* (nuclear protein in testis). Although French *et al* recently published an identical fusion transcript described in paediatric head and neck tumours, this finding has not, to our knowledge, been previously described in lung cancer.[3] In a panel of 128 lung cancer specimens, we did not detect any lung cancers with this translocation, suggesting that this exact alteration is rare in lung cancers. When Brd4-NUT was ectopically expressed *in vitro*, we demonstrated that the fusion protein is localised in the nucleus and inhibits S phase progression. Furthermore, unlike its wild type relative, the fusion protein could not be produced in any appreciable amount in vitro. The present study is the first to describe a balanced translocation in lung cancer and demonstrating a potential function for the identified fusion protein Brd4-NUT in vivo.

MATERIALS AND METHODS
Cell culture, plasmids, and transfection
The t(15;19) lung cancer cell line HCC2429 was established from a 34 year old, non-smoking woman with no family history of cancer.[1] We also established the EBV lymphoblastoid cell line (BL2429) from the peripheral blood of the same patient. These cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. The cell lines 293T, 293H, and NIH3T3 were maintained in Dulbecco's modified essential medium with 10% fetal calf serum. *Brd4* long isoform and *Brd4-NUT* clones were constructed using IMAGE clone 6287189, and PCR amplification of HCC2429 derived

....

Abbreviations: FISH, fluorescent in situ hybridisation; LDI-PCR, long distance inverse polymerase chain reaction

cDNA, with NM_058243 (Brd4) and XM_171724 (NUT) as templates. The clones were sequence verified and subcloned into a pGFP^2-C1 N-terminus fusion vector (Perkin-Elmer Life Sciences, Boston, MA, USA). Plasmid DNA was prepared using standard methods.

Transfection of 293H was accomplished using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations, using 12 µg DNA per 100 mm petri dish. After 48 hours, transfected cells were flow sorted for GFP expression. The cells were then harvested at 0 and at 16 hours after being cultured in the presence of complete medium, stained with propidium iodine and analysed by flow cytometry. BrdU incorporation in 3T3 was determined by incubating cells with BrdU (10 µmol/L) for 30 minutes after transfection with the control, wild type Brd4, and fusion constructs. Because of low transfection efficiency with fusion constructs, the cells were flow sorted using an antibody to GFP and fixed in cold 70% ethanol. The cells were then washed with phosphate buffered saline (PBS) and resuspended in 0.1 mol/L borax with 0.025% Tween and 0.025% BSA. The cells were incubated with primary antibody for 30 minutes, followed by two washes with 0.5% bovine serum albumin/PBS, and incubation with the secondary antibody for 30 minutes. The cells were then washed and resuspended in medium containing propidium iodide.

Pulse chase labelling experiments were carried out using 293T transfected with wild type Brd4 and fusion constructs. Cells were switched to RPMI medium lacking methionine and cysteine 15 min before the addition of 250 µCi of Expre^{35}S^{35}S Protein Labelling Mix (NEN, Torrance, CA, USA) for 1 hour. The labelling pulse was terminated by replacing labelling medium with complete medium. Following the indicated chase period, the cells were lysed in RIPA buffer (20 mmol/L Tris pH 8.5, 100 mmol/L NaCl, 0.2% sodium deoxycholate, 0.2% NP-40, 0.2% Triton X-100, 0.1% sodium dodecyl sulphate, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulphonyl fluoride, 4 µg of aprotinin/ml, 2 µg of pepstatin/ml), and the lysate was clarified by centrifugation at 14 000 g for 15 minutes and immunoprecipitated with GFP mAb (Zymed, San Francisco, CA, USA) and protein G agarose (Sigma, St. Louis, MO, USA). Radiolabelled proteins found in the immunoprecipitate were resolved by reduced sodium dodecyl sulphate polyacrylamide gel electrophoresis, and the dried gel was autoradiographed.

Long distance inverse PCR cloning of *BRD4* rearrangement

High molecular weight DNA from HCC2429 was digested to completion with *Kpn*I and ligated at low concentration to promote the formation of monomeric circles. The DNA was then purified using a Wizard column (Promega, Madison, WI, USA), and 10 ng was amplified in a nested PCR reaction using LA *Taq* polymerase (Takara Bio. Inc., Japan) and primers designed to anneal to the region between two *Kpn*I sites and within exons 11 and 12 of *Brd4*. These primers were: external R31546-F2 (5′-GGGAGACAGTTAACAAAGAGACA-GACAGACAGAGG-3)′ and external R31546-R2 (5′-ACGTG-CAGTGCGGCCGCTTCAGGGAGAT-3′), and nested primers internal R31546-F3 (5′-AGTCACCTAACCTGTTTCGGAGTC-TTCGCTGTC-3)′ and internal R31546-R3 (5′-GATGCTTCGC-TGGTTTCTGGTGGATGTGGA-3)′. After PCR, aliquots of the reaction were run in a 0.8% agarose gel. The band was then excised from the gel, purified using Qiaquick spin columns (Qiagen, Hilden, Germany), and cloned into the *Eco* RV-digested pBluescript SKII(−) (Stratagene, La Jolla, CA, USA) plasmid vector. The sequences were checked against the Genbank sequences using the BLAST program from the US National Center for Biotechnology Information.

Northern blot analysis and exon specific RT-PCR

Total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. Northern blot analysis was performed using 10 µg of total cellular RNA per sample and hybridised with a 0.8 kb *Brd4* cDNA probe (Genbank accession number, NM_058243) and 0.7 kb *NUT* cDNA probes (Genbank accession number, AF482429) respectively. Using RT-PCR, the cDNA was synthesised using 5 µg of total RNA with SuperScript II reverse transcriptase (Invitrogen) and oligo-dT primer (Roche Applied Science, Indianapolis, IN, USA). PCR amplification was carried out to confirm the Brd4-NUT fusion transcript. After 35 rounds of PCR (94℃ for 30 seconds, 55℃ for 30 seconds, 72℃ for 45 seconds), the PCR product was electrophoresed in a 2% agarose gel. The sequences of primers used were Brd4-ex7S (5′-GATAGCTCCTCGGACAGTGA-3′) and LOC-AS1 (5′-CGGCACTAGGTTTCATGCTC-3′).

Fluorescence in situ hybridisation analysis using tissue microarrays

Tissue microarrays were prepared from paraffin blocks of 128 lung tumours (52 cases of squamous cell carcinoma, 45 cases of adenocarcinoma, 9 cases of large cell carcinoma, 1 case of small cell carcinoma, 7 cases of carcinoid tumour, and 14 cases that were classified as non-small cell lung cancers without histological subtype) and from 20 normal lung tissues. Samples were collected from surgeries performed at the Vanderbilt University Medical Center between 1989 and 2000. Haematoxylin and eosin stained sections from all tissue blocks were reviewed by a board certified pathologist, and areas to be cored for array production were selected with marking ink. Cores 0.6 mm in diameter were taken in triplicate from the selected areas of each specimen and inserted into a recipient paraffin block. From the arrays, 5 µm sections were cut, mounted onto charged slides, and subjected to interphase FISH.

Interphase nuclei were probed using dual colour FISH. For the chromosome 15 probe, we used the BAC clone RP11-70A1 (Research Genetics, Huntsville, AL), which is approximately 300 kb 3′ of *NUT*. The chromosome 19 cosmid clone R22329, located approximately 300 kb 5′ of *Brd4*, was obtained from the Lawrence Livermore National Laboratory. Briefly, 2 µg of DNA were labelled by nick translation with either Spectrum Orange dUTP or Spectrum Green dUTP (Vysis, Downers Grove, IL, USA). Tissue sections were deparaffinised, followed by washes in 100% ethanol and 1 mol/L sodium thiocyanate for 10 minutes. The sections were then digested with pepsin (4 mg/ml) in 0.2 mol/L HCl for 8 minutes at 37℃, and dehydrated with a graded ethanol series. Prior to hybridisation, the slides were denatured in 70% formamide/2× SSC for 5 minutes at 72℃, dehydrated in graded ethanol, and incubated with a hybridisation mixture consisting of 50% formamide, 2× SSC, 10 µg Cot-1 DNA, and 100 ng of both Spectrum Orange labelled and Spectrum Green labelled probes. After 48 hours of incubation at 37℃, the slides were washed at 45℃ in 50% formamide/2× SSC for 10 minutes and counterstained with antifade solution containing DAPI. The slides were examined for fluoresecent signals with the MDS system from Applied Imaging. Nuclei in which the nuclear boundaries were broken were excluded from the analysis.

RESULTS
Molecular cloning of t(15,19) breakpoint in HCC2429

We previously described the identification and mapping of a somatically acquired balanced t(15;19) translocation arising in an aggressive, metastatic lung carcinoma. We also localised the breakpoint on chromosome 19p to the 3′ 488 bp region of *Brd4* on between two *Bam*HI sites.[1] Using

positional cloning with fluorescence in situ hybridisation on metaphase arrested cells, the hybridisation signals from cosmid R31546, which contains nearly the entire *Brd4* gene, were found on both der(19) and normal chromosome 19. In our Southern blot mapping of the breakpoint region, DNA digestion with *Kpn*I from HCC2429 showed one rearranged band of 2.6 kb and a considerably larger, germline fragment at 4.2 kb.[1] Based on this finding, we elected to clone the rearranged allele using LDI-PCR) as previously described.[4] Using two pairs of nested primers within the two *Kpn*I sites, a 2.2 kb product was amplified (fig 1A, B). Sequence analysis of the LDI-PCR product identified the precise location of the breakpoint on chromosome 19p and chromosome 15q, and the breakpoint on 19p13.1 was determined to be in the intron between exons 11 and 12 of *Brd4* (fig 1C). The breakpoint on 15q13.2 is approximately 610 bp upstream of a hypothetical gene, *LOC256646*. Recently, this hypothetical gene was renamed as *NUT* (nuclear protein in testis), after it was found to be associated with a t(15;19) in two paediatric head and neck tumours. The function of this gene is unknown, but its expression is reported to be limited to the testis in adults.[3] We also used LDI-PCR to clone the reciprocal breakpoint on der(15). Comparative analysis of the recombined and germline region indicated a complex reciprocal recombination involving a short insertion of chromosome 7 between chromosomes 15 and 19 (data not shown). This finding is not unusual as other neoplasia associated translocations such as t(8;14) in Burkitt's lymphomas, t(9;22) in acute myeloid leukaemia and t(11;22) in Ewing's sarcomas also are rarely true end to end fusions. Instead, they are often accompanied by additional genomic aberrations, such as deletions, insertions, inversions, and duplications.[5–7]

Detection of the Brd4-NUT fusion transcript

As the breakpoint on chromosome 19 lies between exons 11 and 12 in the *Brd4* gene and upstream of transcription start sites of both *NUT* and *NOLA3*, we tested whether the translocation resulted in a fusion transcript containing both *Brd4* and *NUT* sequences. A reverse transcription (RT) PCR analysis was performed using a sense primer from *Brd4* exon 7 (Brd4-ex7S) and an antisense primer from *NUT* (LOC-AS1). We were able to readily amplify the predicted 733 bp fragment in HCC2429 containing the t(15;19), but not in the lymphoblastoid cell line, BL2429 (fig 2A). The PCR product was subcloned, and sequence analysis revealed that nucleotide 2380 (exon 11) of *Brd4* (GenBank accession no. NM_058243) was fused in frame with nucleotide 172 (exon 2) of *NUT* (XM_171724), resulting in a novel 5622 bp fusion transcript (fig 2B, C). This novel fusion transcript in lung cancer is identical to the *BRD4-NUT* fusion transcript recently

reported in two poorly differentiated carcinoma head and neck tumours with t(15;19)(q13;p13.1).[3] Although the transcriptional direction of *NOLA3* on the reciprocal translocation partner was opposite that of *Brd4*, we examined whether the 3' region of *Brd4* (exons 12-20) could fuse with *NOLA3* upstream of *NUT* and centromeric to the breakpoint. As expected, no product was detected (data not shown), suggesting that the 5'-*Brd4*-*NUT*-3' fusion transcript is the only novel product resulting from the t(15;19).

To examine the expression of the *Brd4-NUT* fusion transcript, we performed Northern blot analysis using a Brd4 5'-end cDNA probe on total RNA from HCC2429, BEAS-2B (a normal lung epithelial cell line), and two lung cancer cell lines NCI-H1819 and NCI-H460. A 6.4 kb putative *Brd4-NUT* transcript was expressed only in HCC2429 with t(15;19), whereas a 6.0 kb transcript, but not the 4.4 kb transcript, which probably encode the long and short isoform

Figure 2 (A) Detection of the BRD4-NUT chimeric transcript by RT-PCR with exon specific primers BRD4-S and NUT-AS. The fusion transcript is not detected in BL2429, a lymphoblastoid line from the same patient, suggesting that the translocation is a somatic event. (B) Sequence of the partial fusion transcript showed that BRD4 is fused in frame to NUT. The arrow indicates the breakpoint. (C) Schematic illustration of the *Brd4* long and short isoform, NUT and BRD4-NUT fusion proteins. The breakpoint interrupts the coding sequence of both the long and short isoforms. Of note, both bromodomains and the ET domain are intact in the fusion product. BD, bromodomain, ET, extra-terminal domain.

Figure 1 (A) A 2.2 kb LDI-PCR product was amplified in a nested PCR reaction from circularised genomic DNA digested with *Kpn*I. The 2.2 kb PCR fragment corresponds to the 2.6 kb rearranged band seen on Southern blot analysis (previously published data). (B) A restriction map of rearranged *Brd4* allele. The arrows (R1, F1) and (R2, F2) indicate positions of nested PCR primers, first and second PCR reactions, respectively. Relative positions of FISH probes, RP11-70A17 and R22329 to the breakpoint are indicated. (C) DNA sequence analysis of translocation breakpoint from the 2.2 kb LDI-PCR product. The DNA sequence of derivative 19 (der19) is compared with germline chromosome 19 (CHR19) and 15 (CHR15) sequences.

respectively, was detected in normal and lung cancer cell lines (fig 3A). Using a *NUT* cDNA probe, we were able to detect the fusion transcript in HCC2429 (fig 3B) but not the non-rearranged *NUT* transcript. We analysed *NUT* expression in 20 lung cancer cell lines by RT-PCR, and no expression was found in any of these samples (data not shown). This finding is consistent with previous reports that NUT expression is confined to the testis, and we show that it is also not commonly expressed in lung cancers.

Fluorescence in situ hybridisation analysis in a lung cancer tissue microarray

To determine the frequency of t(15;19) in lung cancer, we used a paraffin based FISH assay, using cosmid probe R22329 upstream of *Brd4* and RP11-70A17 downstream of the *NUT* gene. As a control, a paraffin embedded cell line, HCC2429, was used, which clearly demonstrated the juxtaposition of the *NUT* telomeric (green) signal and the *Brd4* centromeric (red) signal (fig 3C, arrow). We screened a total of 128 lung cancer specimens including 41 adenocarcinomas and 52 squamous cell carcinomas, but no t(15;19) fusion signal was detected. Of note, polyploidy was frequently observed (fig 3C, lower panel).[8] As translocation between chromosomes 15 and 19 appears to be a rare event in lung cancer, we also examined whether the *Brd4* locus is a frequent target for rearrangement in lung cancers. We used fluorescent labelled probes telomeric and centromeric to the Brd4 locus about 400 kb apart to screen the 128 lung tumour tissue arrays. No separation of the two signals was seen (data not shown), suggesting that, like t(15;19), rearrangement of this region near *Brd4* is also not a common event in lung cancer.

## The Brd4-NUT fusion protein localises to the nucleus

To evaluate potential biological activity of the fusion protein, we inserted the Brd4-NUT fusion cDNA clone, and the wild type Brd4 (long isoform) open reading frame into an N-terminal GFP expression vector. Like Brd4, Brd4-NUT localised to the nucleus. The level of fusion protein product was consistently much lower than that observed with Brd4 or GFP alone (fig 4A). In vitro translation of Brd4 short isoform (a rare spliced variant), Brd4, and Brd4-NUT cDNA produced proteins of predicted sizes, as confirmed by Western blot analysis (fig 4B). We placed the fusion construct into different cloning vectors and moved GFP fusion from the C to the N terminal without any appreciable difference in the ability of 293T to express the fusion product (data not shown). Pulse chase analysis with ^{35}S-cysteine and ^{35}S-methionine showed that the low level of fusion product appears to be the result of low synthesis and not of decreased half-life (fig 4C).

The ectopically expressing Brd4-NUT fusion protein inhibits S phase in vitro

Brd4 belongs to the BET family of nuclear proteins that interacts with acetylated chromatin, and overexpression of Brd4 has been reported to inhibit cell cycle progression from G_1 to S phase.[9] Given the role of Brd4 in cycle cell progression, we examined the effect of the fusion product on cell cycle after synchronisation. Inexplicably low expression of fusion protein with transient transfection required that the transfected cells be flow sorted for GFP expression prior to cycle cell analysis. We examined cell cycle profiles immediately after sorting and 16 hours after incubation with complete medium (fig 5A). After sorting with flow cytometry, the vast majority of cells were arrested in G_1. After 16 hours, an appreciable portion of cells transfected with the control vector progressed through S phase and into G_2/M (black arrow). Consistent with previously published data, ectopic expression of Brd4 in 293H results in the delay of progression

Figure 3 (A) Northern blot analysis of BRD4 expression. The 6.4 kb aberrant transcript (1) was detected in HCC2429 with t(15;19), corresponding to BRD4-NUT fusion transcript. A 6.0 kb BRD4 long isoform transcript (2) was detected in all cell lines examined: BEAS2B, an immortalised lung epithelial cell line and the other lung cancer cell lines NCI-H1819 and NCI-H460. However, we did not detect BRD4 short transcript (3). (B) NUT expression (4) was detected only in HCC2429. (C) FISH analysis of paraffin embedded tumour HCC2429 (A) and a representative case of lung cancer (B). The tissue was hybridised with a chromosome 15 probe, RP11-70A17 (green), and a chromosome 19 probe, R22329 (red). A fusion signal can be seen in HCC2429 (arrow) compared with the lung cancer without translocation. Of note, the lower panel shows marked aneuploidy, a common observation in human lung cancers.

Figure 4 Expression of fusion product and wild type Brd4 in transiently transfected 293T. (A) Top, bright field; bottom, dark field. Subcellular localisation of BRD4-NUT and BRD4 long isoform in 293T visualised with fluorescent and bright field microscopy. Similar to BRD4, fusion product is localised in the nucleus. Of note, the level of expression of fusion product is markedly less then that seen with BRD4. The experiment was repeated several times with similar results. In contrast, GFP expression of empty vector is seen in the cytoplasm. (B) Immunblot using a GFP antibody demonstrates constructs (Brd4, Brd4-short isoform (SI) and Brd4-NUT) of expected size. (C) A ^{35}S-pulse chase analysis demonstrated a much lower level of fusion protein compared with that of wild type Brd4. However, the half life of both proteins appeared to be comparable.

from G_1 to S, in which many cells have just exited from G_1 (fig 5A, grey arrow) compared with cell lines transfected with vector control. Interestingly, the cells transfected with the Brd4-NUT protein remained in G_0/G_1, suggesting that the fusion protein product from the t(15;19) enhances normal Brd4 function. The effect of ectopic expression of fusion product on the S phase was also determined by measuring BrdU uptake. Compared with VC and wild type Brd4, BrdU incorporation was severely suppressed, suggesting that ectopic expression of fusion product inhibit S phase progression (fig 5B).

DISCUSSION

Common epithelial tumours such as lung cancer frequently exhibit marked chromosome abnormalities, which can be classified broadly into numerical (aneuploidy) and structural alterations (such as deletions, translocations, and amplifications).[10] To date, a large number of recurrent chromosomal translocations has been identified and characterised in leukaemias, lymphomas, sarcomas, and some rare tumours. In the more common epithelial tumours, recurring reciprocal translocations have not been found. In the present study, we have succeeded in localising the precise breakpoint to chromosome 19 between exons 11 and 12 of *Brd4* and have determined that exon 11 of the *Brd4* gene was fused to the second exon of *NUT*. In addition, we have determined that the breakpoint chromosome 15 lies 610 bp upstream from the first exon of a gene recently named *NUT* (nuclear protein in testis). The t(15;19) is an uncommon but recurring reciprocal chromosome translocation observed in highly aggressive epithelial tumours, and to date, 10 cases, including our index case, have been published in the literature.[1 11 12] Although the precise breakpoints of these translocations are unknown, several have identical fusion products and positive chromosome 15 and 19 rearrangements by dual colour FISH,

suggesting that these translocations are similar to our index case.[3 12]

The HCC2429 cell line was derived from a 34 year old woman who presented with an exophytic mass occluding the right upper lobe anterior segment of the lung with metastasis to bone. Her clinical presentation and extensive pathological diagnosis supported a diagnosis of non-small cell lung cancer. Based on our index case, we wanted to determine the frequency of t(15;19) in lung cancer. However, none of the 128 lung cancers screened by interphase FISH showed co-hybridising fusion signals, indicating that this specific translocation is rare in lung cancer. Furthermore, we were not able to detect rearrangements of the *Brd4* locus using tissue microarray or NUT expression in lung cancer cell lines. Taking together, these findings suggest that neither Brd4 nor NUT is a common target in the development or progression of lung tumours. However, the patients with t(15;19) reported in the literature are commonly younger than our randomly selected population of lung cancer patients, and it is possible that the incidence of this translocation is higher in lung tumours in young patients or in other paediatric tumours.[12]

The *Brd4* gene encodes a putative 1400 amino acid protein characterised by the presence of two bromodomains in the N-terminal region of the protein and an ET domain in the more C-terminal region of the protein. Although Brd4 is reported to have two alternative transcripts, we were not able to detect the short transcript in either normal lung epithelium or cancer cell lines, a finding consistent with the results of Houzelstein *et al*.[13] Bromodomains are evolutionarily conserved 110 amino acid motifs found in several eukaryotic transcription factors, which interact with acetyl lysine, at least in the context of short histone H3 and H4 peptides. The families of proteins containing bromodomains include most nuclear histone acetyltransferases (HATs), the SWI/SNF family of proteins, the CREB binding protein/p300, and the

Figure 5 Ectopic expression of fusion product, Brd4-NUT inhibits S phase progression. (A) Cell cycle analysis demonstrates a delayed progression from G_1 arrest in cells ectopically expressing Brd4 and Brd4-NUT fusion protein (from left, vector, Brd4, Brd4-NUT). 293H cells were flow sorted for GFP expression 48 hours after transfection. After sorting, the majority of cells were in G_1 arrest (0 hours, top). The cells were subsequently released to progress from G_1 by placing them in complete medium. After 16 hours in complete medium (bottom), a large portion of control cells had progressed through the cell cycle, as demonstrated by the higher G_2/M (black arrow). However, cells expressing ectopic Brd4 were starting to enter S phase (grey arrow). Interestingly, cells expressing Brd4-NUT fusion product remained in G_0. (B) Inhibition of S phase by ectopically expressed fusion protein was demonstrated by a very low level of BrdU incorporation (from left, control, Brd4, Brd4-NUT). NIH3T3 cells were pulsed with BrdU for 30 minutes with plasmids expressing control, Brd4, and Brd4-NUT, 48 hours after transfection. Prior to cell cycle analysis, the cells were flow sorted for GFP expression, followed by ethanol fixation. Compared with control, a lower rate of BrdU incorporation was seen in cells transfected with the fusion construct, suggesting that the Brd4-NUT fusion inhibits S phase *in vitro*.

BET proteins. The BET proteins, including Brd4, differ significantly from other bromodomain proteins in their coding sequence and carry two tandem bromodomains with a C-terminal extraterminal domain.[14] Using fluorescence photobleaching, Brd4 was found to interact with acetylated chromatin in living cells in a bromodomain dependent manner, and this interaction was shown to be crucial for progression through the G_2/M transition.[15] Furthermore, other investigators have shown that ectopic expression of Brd4 induces G_1 arrest and inhibits S phase progression through binding with replication factor C.[9] Thus, it is clear from our data and from the literature that perturbation of Brd4 alters cell cycle kinetics.

The fusion transcript retains both bromodomains and the BET domain in the NH_2-terminus. The mechanism by which t(15;19)(q13.2;p13.1) contributes to the tumorigenesis of lung cancer remains unclear. Studies of deletion mutants have shown that the bromodomains are important for chromatin interaction.[9 14] Interestingly, although the function of the C-terminal domain is relatively unknown, studies of Brd4 deletion mutants retaining both bromodomains but lacking the C-terminal domain enhance binding to chromatin in the presence of trichostatin A, a histone deacetylase inhibitor. Furthermore, the ΔC mutant enhances Brd4 interaction with GTPase activity of SAP-1 and inhibits progression to S phase.[16] These observations suggest that the C-terminal domain negatively regulates Brd4 interactions with chromatin. The loss of the C-terminal domain by the translocation, juxtaposing the NUT transcript, may therefore enhance Brd4 activity. This hypothesis is supported by our observation that the fusion protein inhibits G_1/S phase progression to a greater degree than wild type Brd4.

Virtually all known fusion products as a result of recurrent translocation have been demonstrated to have oncogenic activity. Thus, it is unclear how the inhibition of S phase progression by ectopic expression of fusion product can contribute to lung cancer tumorigenesis. Other investigators have shown that Brd4 expression is induced by growth factors and that its normal expression is important for G_2 to M progression; whether this observation is part of a positive or negative feedback response is undetermined.[14] In our study, malignant transformation was not observed using transformation assays with NIH3T3 and Rat-1A. In addition, cells transfected with the fusion construct died, or stable transfected cells did not express fusion product (data not shown).

While the low expression of fusion protein may be related to a transfection aberrance unique to this construct, it is possible that Brd4 functions as a tumour suppressor gene, owing to its role in cell cycle arrest, and that the t(15;19) translocation results in haploid insufficiency. Another possibility is that, similar to some fusion oncogenes such as *BCR-ABL*, further genetic insults are required for transformation Rat-1 cells.[17] The breakpoint on chromosome 19 is 45 kb upstream of *Notch3*, a gene important in cancer and cell fate determination. This translocation is associated with high

expression of Notch3, a receptor from a family of proteins important in cellular differentiation and cancer.[1][18][19] Thus, a cooperative locus effect cannot be discounted. Finally, ectopic expression of cell cycle proteins such as Brd4 in an in vitro system is a highly artificial environment and may not reflect their true function. Thus, in vivo and further confirmatory studies are needed to assess the true role of t(15;19) and Brd4-NUT in neoplastic transformation.

. . . .

Authors' affiliations

N Haruki, Department of Surgery, Nagoya City Hospital, Nagoya, Japan

K S Kawaguchi, S Eichenberger, D P Carbone, T P Dang, Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA

P P Massion, Division of Allergy/Pulmonary and Critical Care, Vanderbilt University Medical Center, Nashville, TN, USA

A Gonzalez, Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA

A F Gazdar, J D Minna, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA

REFERENCES

1 **Dang TP**, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. *J Natl Cancer Inst* 2000;**92**:1355–7.
2 **Winston F**, Allis CD. The bromodomain: a chromatin-targeting module? *Nat Struct Biol* 1999;**6**:601–4.
3 **French CA**, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. *Cancer Res* 2003;**63**:304–7.
4 **Willis TG**, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer M. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. *Blood* 1998;**91**:1873–81.
5 **Neri A**, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. *Proc Natl Acad Sci USA*, 1988;**85**:2748–52.
6 **Jeffs AR**, Benjes SM, Smith TL, Sowerby SJ, Morris CM. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. *Hum Mol Genet* 1998;**7**:767–76.
7 **Zucman-Rossi J**, Legoix P, Victor JM, Lopez B, Thomas G. Chromosome translocation based on illegitimate recombination in human tumors. *Proc Natl Acad Sci USA*, 1998;**95**:11786–91.
8 **Massion PP**, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. *Cancer Res* 2003;**63**:7113–21.
9 **Maruyama T**, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T, Sciortino S, Shuman J, Hurwitz J, Ozato K. A mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. *Mol Cell Biol* 2002;**22**:6509–20.
10 **Lengauer C**, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998;**396**:643–9.
11 **Kees UR**, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). *Am J Pediatr Hematol Oncol* 1991;**13**:459–64.
12 **French CA**, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, Nose V, Vargas SO, Moschovi M, Tzortzatou-Stathopoulou F, Miyoshi I, Perez-Atayde AR, Aster JC, Fletcher JA. Midline carcinoma of children and young adults with NUT rearrangement. *J Clin Oncol* 2004;**22**:4135–9.
13 **Houzelstein D**, Bullock SL, Lynch DE, Grigorieva EF, Wilson VA, Beddington RS. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. *Mol Cell Biol* 2002;**22**:3794–802.
14 **Dey A**, Ellenberg J, Farina A, Coleman AE, Maruyama T, Sciortino S, Lippincott-Schwartz J, Ozato K. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. *Mol Cell Biol* 2000;**20**:6537–49.
15 **Dey A**, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. *Proc Natl Acad Sci USA* 2003;**100**:8758–63.
16 **Farina A**, Hattori M, Qin J, Nakatani Y, Minato N, Ozato K. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. *Mol Cell Biol* 2004;**24**:9059–69.
17 **Lugo TG**, Witte ON. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. *Mol Cell Biol* 1989;**9**:1263–70.
18 **Axelson H**. Notch signaling and cancer: emerging complexity. *Semin Cancer Biol* 2004;**14**:317–19.
19 **Dang TP**, Eichenberger S, Gonzalez A, Olson S, Carbone DP. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. *Oncogene* 2003;**22**:1988–97.